Storys zum Thema Medicale

12.06.2017 – 23:16
Novo Nordisk
Tresiba® Demonstrated No Increased Risk Of Major Cardiovascular Events and Significant Reduction in Rates of Severe Hypoglycaemia Compared to Insulin Glargine U100 in the DEVOTE Trial
San Diego (ots/PRNewswire) - Symposium: 3-CT-SY22 Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target, event-driven trial comparing two basal insulins, Tresiba® (insulin degludec injection 100 U/mL) and insulin glargine U100, in adults with type 2 ...
mehr
10.06.2017 – 19:02
Novo Nordisk
Switching to Tresiba® Provides Significant Reductions in Blood Glucose and Lower Rates of Hypoglycaemia in a Real-world Setting
Bagsværd, Denmark (ots/PRNewswire) - Poster Presentations #999-P, #1010-P, #1014-P Findings from the real-world study, EU-TREAT (EUropean TREsiba AudiT), were presented today at the American Diabetes Association's 77th Scientific Sessions (ADA) in San Diego, US. The study showed that people with type 1 diabetes and ...
mehr
07.06.2017 – 17:32
Johnson & Johnson Medical GmbH
Johnson & Johnson Medical Devices Launches CareAdvantage, Offering Tailored Support to Help Hospitals and Healthcare Providers in EMEA to Increase Patients' Outcomes and Reduce Costs
Norderstedt, Germany (ots/PRNewswire) - Leveraging 130 years of knowledge and expertise across the Johnson & Johnson Family of Companies, Johnson & Johnson Medical Devices (JJMD) is proud to launch a new approach to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA) - ...
mehr
01.06.2017 – 15:00
Debiopharm International SA
GenePOC announces FDA clearance for revogene(TM) instrument and its GBS LB test
Québec, Canada and Lausanne, Switzerland (ots) - GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its first molecular assay to detect Group B Streptococcus and for the revogene molecular diagnostics instrument. GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is pleased to announce that it has received FDA ...
mehr
01.06.2017 – 14:02
Royal Philips
Scientific Research Highlights Potential of MR-HIFU Technology for New Cancer Therapies
Amsterdam (ots/PRNewswire) - Proceedings of the National Academy of Science (PNAS) paper* details results of a pre-clinical study into the combined use of drug-loaded temperature sensitive liposomes and MR-HIFU for local tumor treatment. Royal Philips (http://www.philips.com) (NYSE: PHG, AEX: PHIA), a leader in health technology, today announced the publication of a ...
mehr
01.06.2017 – 14:00
Debiopharm International SA
Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284
Lausanne, Switzerland (ots) - Debio 1347/CH5183284 was evaluated in patients with FGFR genomically activated advanced solid tumors Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the results from the phase I ...
mehr

31.05.2017 – 13:01
Resverlogix Corp.
Resverlogix to Host Epigenetics Focused Symposium at The ERA-EDTA Congress in Madrid, Spain
Calgary, Alberta (ots/PRNewswire) - The symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" at the ERA-EDTA Congress highlights BET-inhibition and apabetalone in addressing the significant unmet medical need in chronic kidney disease and cardiovascular disease. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced ...
mehr
31.05.2017 – 12:03
Merck Healthcare Germany
Merck Honors World MS Day by Launching Care Partner Survey with IACO
Darmstadt, Germany (ots/PRNewswire) - - Preliminary research indicates most MS carers are between the ages of 18-34, the prime of their lives - Largest global MS carer survey with International Alliance of Carer Organizations (IACO) to help identify unmet needs and social impact Merck, a leading science and technology company, honors World MS Day 2017 by announcing a ...
mehr
30.05.2017 – 13:01
Resverlogix Corp.
Resverlogix Receives Approval From Health Canada to Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
Calgary, Alberta (ots/PRNewswire) - Apabetalone expands in to first orphan disease clinical trial in patients with Fabry disease Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that it has received approval from Health Canada, Therapeutic Products Directorate, to proceed with a clinical ...
mehr
24.05.2017 – 15:31
OncoQuest Inc.
OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
Edmonton, Alberta (ots/PRNewswire) - OncoQuest Inc. ("OncoQuest"), a privately held, biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, today announced the presentation of initial safety and efficacy data from the company's ...
mehr
24.05.2017 – 08:00
Debiopharm International SA
Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen
Lausanne, Switzerland and Waltham, Mass. (ots) - Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value Debiopharm International SA ...
mehr
23.05.2017 – 13:01
Resverlogix Corp.
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
Calgary, Alberta (ots/PRNewswire) - Nature Reviews Nephrology and Pfizer Inc. discuss BET bromodomain inhibition and apabetalone as viable drug candidates Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today highlighted two additional works involving its lead drug, apabetalone, one recently published ...
mehr

22.05.2017 – 08:01
LEO Pharma
Brodalumab, a Novel Biologic for People with Moderate-to-Severe Psoriasis, Receives Positive Opinion from European CHMP
Ballerup, Denmark (ots/PRNewswire) - Opinion from CHMP: "On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product [brodalumab], intended for the treatment of psoriasis[...]The benefits with ...
mehr
19.05.2017 – 18:06
LEO Pharma
Brodalumab, a Novel Biologic for People with Moderate-to-Severe Psoriasis, Receives Positive Opinion from European CHMP
Ballerup, Denmark (ots/PRNewswire) - Opinion from CHMP: "On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product [brodalumab], intended for the treatment of psoriasis[...]The benefits with ...
mehr
19.05.2017 – 15:09
Merieux Developpement
Mérieux Développement Announces Equity Financing into Xeris Pharmaceuticals
Lyon, France and Boston (ots/PRNewswire) - Mérieux Développement has recently concluded an equity investment into Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of injectable drugs. With this additional financing, Xeris Pharmaceuticals expects to fund registration trials and ...
mehr
19.05.2017 – 07:01
Shire Pharmaceuticals Group Plc
Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology
Zug, Switzerland (ots/PRNewswire) - New clinical and real-life data in chronic hypoparathyroidism, to advance understanding of this rare disease and improve patients' lives Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, announced today new research to be presented on rhPTH(1-84) and on the ...
mehr
18.05.2017 – 16:38
National Cancer Centre Singapore (NCCS) and Singapore Clinical Research Institute (SCRI)
American Society of Clinical Oncology (ASCO) Publishes Abstract of SIRveNIB, an Investigator-led Asia Pacific Primary Liver Cancer Study to be Presented at ASCO Annual Meeting in Chicago, 4 June 2017
Singapore (ots/PRNewswire) - The SIRveNIB abstract published on-line in the Journal of Clinical Oncology states that treatment of locally advanced Hepatocellular Carcinoma (HCC) with a single treatment of SIR-Spheres® Y-90 resin microspheres results in Overall Survival not significantly different from twice-daily ...
mehr
18.05.2017 – 15:02
Shire Pharmaceuticals Group Plc
The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis
Dublin (ots/PRNewswire) - - Study met primary endpoint demonstrating significantly greater remission rates in patients receiving anti-MAdCAM antibody (SHP647) compared to placebo in three of four tested dose groups - First study to investigate the potential role of anti-MAdCAM antibody in the management of ...
mehr

18.05.2017 – 13:01
Shire Pharmaceuticals Group Plc
Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial
Lexington, Massachusetts (ots/PRNewswire) - - Significant reduction in monthly Hereditary Angioedema (HAE) attack rate with infrequent subcutaneous administration - Data to serve as basis for U.S. BLA filing expected in Q4 2017 to Q1 2018 - Shire to host Investor Call today at 10 a.m. ET; details below Shire plc ...
mehr
17.05.2017 – 23:02
Merck Healthcare Germany
Shaping Cancer Care Today and Tomorrow: Merck to Present New Data from Rapidly Evolving Pipeline at ASCO 2017
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or U.S.-based media ASCO Abstract # M7824 (anti-PD-L1/TGF-ß trap): 3006; Avelumab: 9086, 9530, 9557, 4528, 3059, 5037, e21070, e21065, e20581; Tepotinib: 4087, 8547, e15676, 20541; M3814 (DNA-PK): 2556, e14048; M7583 (BTKi): e14101 - ASCO data highlights ...
mehr
17.05.2017 – 23:01
Merck Healthcare Germany
Merck and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - A total of 13 abstracts across seven hard-to-treat cancers highlight the progress of avelumab as a monotherapy and potential novel combination treatment option - New data in metastatic Merkel cell carcinoma and ...
mehr
17.05.2017 – 16:31
Novo Nordisk
Early Response to Saxenda® Resulted in Weight Maintenance and Additional Weight Loss Over 56 Weeks
Porto, Portugal (ots/PRNewswire) - Abstract# RS3:3 Today, results from a post hoc analysis of data from the SCALE Maintenance trial were presented at the 24th European Congress on Obesity (ECO) 2017. In the trial, adults who lost at least 5% of their initial weight during a low- calorie run-in period were randomised ...
mehr
15.05.2017 – 16:30
Resverlogix Corp.
Resverlogix Receives Approval From the FDA Cardiovascular and Renal Division to Proceed With a Requested Apabetalone Clinical Trial
Calgary, Alberta (ots/PRNewswire) - Apabetalone expands to a second major clinical indication in kidney dialysis patients Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the acceptance, by the Cardiovascular and Renal Products Division of the U.S. Food and Drug Administration ...
mehr
11.05.2017 – 13:41
Accuray Europe
Accuray: New Data Reinforce Benefits of TomoTherapy® Platform for Mainstream Radiation Therapy Treatment Indications
Sunnyvale, California (ots/PRNewswire) - Multiple Studies Presented at ESTRO 36 Demonstrate System Improves Tumor Control with Reduced Toxicities Accuray Incorporated (NASDAQ: ARAY) announced today that studies continue to demonstrate the unmatched flexibility of the cutting-edge TomoTherapy® System to treat, with ...
mehr

11.05.2017 – 13:31
Accuray Europe
Accuray: New Data Presented at ESTRO 36 Reinforce Unmatched Versatility and Precision of the CyberKnife® System
Sunnyvale, California (ots/PRNewswire) - Studies Show the System Provides Excellent Outcomes Throughout the Cancer Treatment Journey, from Primary Cases to Recurrence and Metastatic Disease Accuray Incorporated (NASDAQ: ARAY) announced today that studies on the clinical use of the leading-edge CyberKnife® System ...
mehr
11.05.2017 – 13:16
Norgine GmbH
Merus Labs and Norgine Enter Into a Definitive Arrangement Agreement
Toronto and Amsterdam (ots/PRNewswire) - - Norgine to acquire all outstanding shares of Merus for $1.65 per share in cash Merus Labs International Inc. ("Merus" or the "Company") TSX: MSL, NASDAQ: MSLI and Norgine B.V. ("Norgine") announced today that they have entered into a definitive agreement (the "Arrangement Agreement") under which Norgine will acquire all of the issued and outstanding common shares of Merus for ...
mehr
11.05.2017 – 09:03
Leica Biosystems Ltd
Leica Biosystems Applauds FDA Primary Diagnosis Clearance as a Step Forward in Clinical Acceptance of Digital Pathology
Vista, California (ots/PRNewswire) - The digital pathology industry just took another step forward, with the FDA clearance of a whole slide imaging (WSI) system (Philips IntelliSite(TM) Pathology Solution) for review of digital surgical pathology slides. Leica Biosystems congratulates both the FDA and the Digital ...
mehr
10.05.2017 – 15:16
Merck Healthcare Germany
European Commission Grants Approval for Merck's New Pergoveris® Pen for Fertility Treatment
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. and UK based media - With this approval, Pergoveris® becomes the first product with a combination of FSH and LH hormones in a ready-to-use liquid version - The new pre-filled injection device for self-administration increases ease-of-use for patients ...
mehr
10.05.2017 – 11:00
Grünenthal Gruppe
Grünenthal opens Innovation Hub in Boston as next step in strategy to drive external innovation in pain, specialty therapeutics and medical devices forward
Aachen, Germany (ots) - - Grünenthal's new Innovation Hub in Greater Boston, U.S., shall accelerate easier access to and close collaboration with leading scientists and institutions - Grünenthal brings fully integrated R&D capabilities in pain to this community - there is no other company with so much focus on ...
mehr
09.05.2017 – 22:07
Merck and Pfizer
FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Darmstadt, Germany, and New York (ots/PRNewswire) - - Second approval for BAVENCIO in less than two months - Advanced urothelial carcinoma is an aggressive disease with a high rate of recurrence Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection for the treatment of patients with ...
mehr

Vorherige28293031323334353637Nächste